Switching to milder treatment versus continuing strong treatment for stable multiple sclerosis

This trial is testing whether patients with relapsing-remitting multiple sclerosis who have been stable on anti-CD20 therapies (strong immunosuppressive medications like ocrelizumab, rituximab, or ofatumumab) can safely switch to milder, longer-established medications. Researchers want to know if this medication can be stepped down without the disease becoming active again, especially in patients who are 40 years or older and have had no disease activity for at least three years.

Anti-CD20 therapies are very effective but are strong immunosuppressive medications with potential long-term risks. This trial exists to find out whether patients who have achieved stable disease control can safely use less aggressive treatment, which could reduce side effects and improve quality of life while maintaining disease control.